Frontiers in Immunology,
Год журнала:
2024,
Номер
15
Опубликована: Янв. 30, 2024
Non-alcoholic
fatty
liver
disease
(NAFLD)
exhibits
increased
lipid
enrichment
in
hepatocytes.
The
spectrum
of
this
includes
stages
such
as
nonalcoholic
simple
(NAFL),
steatohepatitis
(NASH),
and
fibrosis.
Changes
lifestyle
behaviors
have
been
a
major
factor
contributing
to
the
cases
NAFLD
patients
globally.
Therefore,
it
is
imperative
explore
pathogenesis
NAFLD,
identify
therapeutic
targets,
develop
new
strategies
improve
clinical
management
disease.
Immunoregulation
strategy
through
which
organism
recognizes
eliminates
antigenic
foreign
bodies
maintain
physiological
homeostasis.
In
process,
multiple
factors,
including
immune
cells,
signaling
molecules,
cytokines,
play
role
governing
evolution
NAFLD.
This
review
seeks
encapsulate
advancements
research
regarding
regulation
spanning
from
underlying
mechanisms
practical
applications.
Hepatology,
Год журнала:
2023,
Номер
77(4), С. 1335 - 1347
Опубликована: Янв. 3, 2023
Background
and
Aims:
NAFLD
is
a
leading
cause
of
liver-related
morbidity
mortality.
We
assessed
the
global
regional
prevalence,
incidence,
mortality
using
an
in-depth
meta-analytic
approach.
Approach
Results:
PubMed
Ovid
MEDLINE
were
searched
for
population-based
studies
from
1990
to
2019
survey
year
(last
published
2022)
per
Preferred
Reporting
Items
Systematic
Reviews
Meta-Analyses
(PRISMA).
Meta-analysis
was
conducted
random-effects
models.
Bias
risk
assessment
Joanna
Briggs
Institute.
Of
2585
reviewed,
92
(N=9,361,716)
met
eligibility
criteria.
Across
study
period
(1990–2019),
pooling
prevalence
estimates
ultrasound-defined
yielded
overall
30.05%
(95%
CI:
27.88%–32.32%)
30.69%
(28.4–33.09),
respectively.
Global
increased
by
+50.4%
25.26%
(21.59–29.33)
in
1990–2006
38.00%
(33.71–42.49)
2016–2019
(
p
<0.001);
+38.7%
25.16%
(19.46–31.87)
34.59%
(29.05–40.57)
=0.029).
The
highest
Latin
America
44.37%
(30.66%–59.00%),
then
Middle
East
North
Africa
(MENA)
(36.53%,
28.63%–45.22%),
South
Asia
(33.83%,
22.91%–46.79%),
South-East
(33.07%,
18.99%–51.03%),
(31.20%,
25.86%–37.08%),
(29.71%,
25.96%–33.76%),
Pacific
28.02%
(24.69%–31.60%),
Western
Europe
25.10%
(20.55%–30.28%).
Among
cohort
diagnosed
without
liver
biopsy,
pooled
rate
1000
PY
12.60
(6.68–23.67)
all-cause
mortality;
4.20
(1.34–7.05)
cardiac-specific
2.83
(0.78–4.88)
extrahepatic
cancer-specific
0.92
(0.00–2.21)
liver-specific
Conclusions:
30%
increasing
which
requires
urgent
comprehensive
strategies
raise
awareness
address
all
aspects
on
local,
regional,
levels.
Hepatology Communications,
Год журнала:
2023,
Номер
7(10)
Опубликована: Окт. 1, 2023
Background:
The
latest
meta-analyses
suggest
NAFLD
is
increasing
globally.
Its
limitations
may
preclude
accurate
estimates.
We
evaluated
the
global
burden
and
its’
trends
in
prevalence
liver–related
mortality
(LRM)
by
sex,
age,
region,
country
over
past
3
decades
using
data
from
Global
Burden
of
Disease
(GBD)
2019
study.
Methods:
Crude
age-standardized
NAFLD-LRM
rates
were
obtained
for
all-age
individuals
with
204
countries/territories
between
1990
2019.
Joinpoint
trend
analysis
assessed
time
trends.
Weighted
average
annual
percent
change
(APC)
period
1990–2019
2010–2019
reported.
Results:
All-age
(children
adults)
crude
increased:10.5%
(561
million)–16.0%
(1,236
million);
an
APC
increase:
+
1.47%
(95%
CI,
1.44%,
1.50%).
Among
adults
(+20
y),
increased
(1990:
17.6%,
2019:23.4%;
APC:
1.00%,
95%
CI:
0.97%,
1.02%).
In
groups,
rate
(per
100,000)
1.75%,
2019:
2.18%;
0.77%
0.70%,
0.84%).
By
analysis,
2010
to
2019,
worsening
LRM
observed
among
202
167
countries,
respectively.
there
1.24
billion
prevalent
cases
168,969
associated
deaths;
Asia
regions
accounted
57.2%
46.2%
NAFLD-LRM.
highest
was
Middle
East
North
Africa
(LRM
26.5%);
Central
Latin
America
(5.90
per
100,000).
Conclusions:
globally
groups—over
80%
countries
experienced
increase
These
have
important
policy
implications
affected
health.
Journal of Translational Medicine,
Год журнала:
2023,
Номер
21(1)
Опубликована: Июль 28, 2023
Metabolic
dysfunction-associated
fatty
liver
disease
(MAFLD)
is
among
the
most
widespread
metabolic
globally,
and
its
associated
complications
including
insulin
resistance
diabetes
have
become
threatening
conditions
for
human
health.
Previous
studies
on
non-alcoholic
(NAFLD)
were
focused
liver's
lipid
metabolism.
However,
growing
evidence
suggests
that
mitochondrial
metabolism
involved
in
pathogenesis
of
NAFLD
to
varying
degrees
several
ways,
instance
cellular
division,
oxidative
stress,
autophagy,
quality
control.
Ultimately,
function
gradually
declines
as
a
result
dysfunction.
The
unable
transfer
excess
droplets
outside
liver.
Therefore,
how
regulate
hepatic
treat
has
focus
current
research.
This
review
provides
details
about
intrinsic
link
with
mechanisms
by
which
dysfunctions
contribute
progression.
Given
crucial
role
progression,
application
potential
multiple
improvement
modalities
(including
physical
exercise,
diabetic
medications,
small
molecule
agonists
targeting
Sirt3,
mitochondria-specific
antioxidants)
treatment
was
evaluated
hoping
provide
new
insights
into
treatment.
Journal of Agricultural and Food Chemistry,
Год журнала:
2024,
Номер
unknown
Опубликована: Апрель 12, 2024
Nonalcoholic
fatty
liver
disease
(NAFLD)
is
characterized
by
fat
accumulation
and
inflammation.
Epigallocatechin
gallate
(EGCG)
has
been
proven
to
be
effective
against
NAFLD,
but
its
hepatoprotective
mechanisms
based
on
the
"gut
microbiota-barrier-liver
axis"
are
still
not
fully
understood.
Herein,
results
demonstrated
that
EGCG
effectively
ameliorated
NAFLD
phenotypes
metabolic
disorders
in
rats
fed
a
high-fat
diet
(HFD),
inhibited
intestinal
barrier
dysfunction
inflammation,
which
also
supported
experiment
of
Caco-2
cells.
Moreover,
could
restore
gut
microbiota
diversity
composition,
particularly
promoting
beneficial
microbes,
including
short-chain
acids
(SCFAs)
producers,
such
as
Lactobacillus,
suppressing
Gram-negative
bacteria,
Desulfovibrio.
The
microbial
modulation
raised
SCFA
levels,
decreased
lipopolysaccharide
TLR4/NF-κB
pathway,
strengthened
function
via
Nrf2
pathway
activation,
thereby
alleviating
steatosis
Spearman's
correlation
analysis
showed
24
key
OTUs,
negatively
or
positively
associated
with
disorders,
were
reshaped
EGCG.
Our
suggested
combinative
improvement
dysbiosis,
dysfunction,
inflammation
might
potential
therapeutic
target
for
NAFLD.
Biomedicines,
Год журнала:
2024,
Номер
12(2), С. 397 - 397
Опубликована: Фев. 8, 2024
Non-alcoholic
fatty
liver
disease
(NAFLD)
is
a
widespread
contributor
to
chronic
globally.
A
recent
consensus
on
renaming
was
established,
and
metabolic
dysfunction-associated
steatotic
disease,
MASLD,
chosen
as
the
replacement
for
NAFLD.
The
disease’s
range
extends
from
less
severe
previously
known
non-alcoholic
(NAFL),
more
intense
steatohepatitis
(MASH),
(NASH),
characterized
by
inflammation
apoptosis.
This
research
project
endeavors
comprehensively
synthesize
most
studies
encompassing
wide
spectrum
of
topics
such
pathophysiology,
risk
factors,
dietary
influences,
lifestyle
management,
genetics,
epigenetics,
therapeutic
approaches,
prospective
trajectory
particularly
exploring
its
connection
with
organoids.
